Skip to main content

SeaStar Medical Holding Corp

corporate_fare Company Profile

SeaStar Medical Holding Corp

ICU·NASDAQ·Industrial Applications And Services·CIK 0001831868

SeaStar Medical is a commercial-stage healthcare company developing treatments for critically ill patients experiencing organ failure. The company's primary product is the Selective Cytopheretic Device ("SCD"), a device designed to neutralize over-active immune cells and stop cytokine storms that cause hyperinflammation. The SCD has potential applications for patients with acute and chronic kidney disease, cardiovascular disease, and other inflammatory conditions. On February 21, 2024, SeaStar Medical received Food and Drug Administration ("FDA") approval under a Humanitarian Device Exemption ("HDE") for its pediatric SCD therapy. This product, branded "QUELIMMUNE," is the only FDA-approved product for pediatric patients with acute kidney injury ("AKI") due to sepsis or a septic condition requiring kidney replacement therapy. The first commercial pediatric SCD was shipped in July 2024. The company is also conducting a pivotal clinical trial, "NEUTRALIZE-AKI," to evaluate the safety and efficacy of SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy ("CRRT"). Additionally, a feasibility study is underway for SCD therapy in adult patients with Cardiorenal Syndrome ("CRS") awaiting left ventricular assist device ("LVAD") implantation. The FDA has granted six Breakthrough Device Designations ("BDD") for the SCD therapy, covering multiple indications in adult patients, including AKI, CRS awaiting LVAD implantation, hepatorenal syndrome, end-stage renal disease ("ESRD"), and systemic inflammatory response during cardiac surgery.

SeaStar Medical Holding Corp (NASDAQ:ICU) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 25 items for ICU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for ICU spans 8-K, 10-Q, 8-K/A, 424B3.

Recent high-impact activity:

  • SeaStar Medical Hit With Nasdaq Deficiency Notice on $2.5M Equity Rule
  • SeaStar 10-Q: Q3 Revenue Up 247% to $635K, But Going Concern Flags $3.99M Cash
  • SeaStar Q3 Revenue Up 247% but NEUTRALIZE-AKI Enrollment Slips to Mid-2027
  • SeaStar Medical Posts $4.5M Q3 Net Loss as Operating Expenses Hit $5.2M
  • FDA Clears QUELIMMUNE Post-Approval Study Requirement, Opening Therapy to More Pediatric Centers

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.23M
Net Income
-$12.15M
Op. Cash Flow
-$13.6M
Gross Profit
$1.18M
Operating Income
-$12.18M
Cash & Equivalents
$11.98M
Debt / Equity
0.00×
Net Margin
-9.85×
Shares Outstanding
3.84M sh
Source: 10-K · filed 2026-03-25 · accession 0001437749-26-009797

Short Interest & Short Volume

1.33 days to cover

FINRA reported short interest of 175,168 shares in ICU as of the October 30, 2026 settlement, a 5.7% decrease from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 36.3% of ICU volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)175,168 shares as of October 30, 2026
Change vs prior period▼ 5.7%
Days to cover1.33 at avg daily volume of 132,096
Daily short volume (FINRA facilities)36.3% of 69,878 shares on November 20, 2026
5-day average short volume53.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ICU, detected from its recent SEC filings · based on capital-structure filings through 2026-10-30.

1 shelf registration

Resale Registration of Inducement Warrants · No Proceeds From Resales

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$0.8919 -4.61% today
52-week range · as of 2026-11-20 $0.761 – $5.38
Market cap
$4.97M
Volume
135.8K (0.5× avg)
3-mo avg 276.8K
Live data · 2026-11-21 22:11 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ICU - Latest Insights

ICU
Nov 20, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9101
Real-time Price: $0.8919 info
Change: -$0.0182 (-2%) info
Market Cap: $4.97M info
ICU
Nov 12, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $0.8919 info
Change: -$0.7781 (-47%) info
Market Cap: $4.97M info
ICU
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $0.8919 info
Change: -$0.7781 (-47%) info
Market Cap: $4.97M info
ICU
Nov 11, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.8919 info
Change: -$1.03 (-54%) info
Market Cap: $4.97M info
ICU
Nov 03, 2026, 8:21 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $0.8919 info
Change: -$1.51 (-63%) info
Market Cap: $4.97M info
ICU
Oct 22, 2026, 12:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.22
Real-time Price: $0.8919 info
Change: -$2.33 (-72%) info
Market Cap: $4.97M info
ICU
Oct 07, 2026, 8:16 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $0.8919 info
Change: -$2.37 (-73%) info
Market Cap: $4.97M info
ICU
Oct 05, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $0.8919 info
Change: -$2.65 (-75%) info
Market Cap: $4.97M info
ICU
Aug 12, 2026, 4:46 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $0.8919 info
Change: -$2.31 (-72%) info
Market Cap: $4.97M info
ICU
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.36
Real-time Price: $0.8919 info
Change: -$2.47 (-73%) info
Market Cap: $4.97M info
ICU
Jul 01, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.71
Real-time Price: $0.8919 info
Change: -$3.82 (-81%) info
Market Cap: $4.97M info
ICU
Jun 23, 2026, 4:14 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $0.8919 info
Change: -$2.58 (-74%) info
Market Cap: $4.97M info
ICU
Jun 23, 2026, 8:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.29
Real-time Price: $0.8919 info
Change: -$2.40 (-73%) info
Market Cap: $4.97M info
ICU
Jun 17, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $0.8919 info
Change: -$2.17 (-71%) info
Market Cap: $4.97M info
ICU
May 13, 2026, 4:57 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $0.8919 info
Change: -$3.99 (-82%) info
Market Cap: $4.97M info
ICU
May 13, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $0.8919 info
Change: -$3.99 (-82%) info
Market Cap: $4.97M info
ICU
May 13, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.89
Real-time Price: $0.8919 info
Change: -$4.00 (-82%) info
Market Cap: $4.97M info
ICU
May 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.60
Real-time Price: $0.8919 info
Change: -$3.71 (-81%) info
Market Cap: $4.97M info
ICU
May 07, 2026, 8:38 AM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $4.87
Real-time Price: $0.8919 info
Change: -$3.98 (-82%) info
Market Cap: $4.97M info
ICU
Apr 28, 2026, 4:45 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $3.92
Real-time Price: $0.8919 info
Change: -$3.03 (-77%) info
Market Cap: $4.97M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets